EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Biomarker, efficacy and safety analysis of transcatheter arterial chemoembolization combined with atezolizumab and bevacizumab for unresectable hepatocellular carcinoma

Shaobo Zhang, Zebin Zhu, Lianxin Liu, Björn Nashan, Shugeng Zhang

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-04058-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Shaobo Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Transplantation, Division of Life Science and Medicine, The First Affiliated Hospital of USTC, University of Science and Technolo…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Bevacizumab, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsBevacizumabAntibodies, Monoclonal, HumanizedChemoembolization, TherapeuticAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorHumansMaleFemaleMiddle AgedRetrospective StudiesAgedNeutrophilsAdultTreatment Outcome

Stichwörter der Autor:innen

AtezolizumabBevacizumabBiomarkersHepatocellular carcinomaTransarterial chemoembolization

Substanzen

BevacizumabAntibodies, Monoclonal, HumanizedatezolizumabBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Liver Transplantation, Division of Life Science and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, 230000, Anhui, China.
  • Department of Liver Transplantation, Division of Life Science and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, 230000, Anhui, China. bjoern.nashan@gmail.com.
  • Department of Liver Transplantation, Division of Life Science and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, 230000, Anhui, China. zsg0517@ustc.edu.cn.

Zitieren

APA

Zhang, S., Zhu, Z., Liu, L., Nashan, B., & Zhang, S. (2025). Biomarker, efficacy and safety analysis of transcatheter arterial chemoembolization combined with atezolizumab and bevacizumab for unresectable hepatocellular carcinoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04058-4

Vancouver

Zhang S, Zhu Z, Liu L, Nashan B, Zhang S. Biomarker, efficacy and safety analysis of transcatheter arterial chemoembolization combined with atezolizumab and bevacizumab for unresectable hepatocellular carcinoma. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04058-4

BibTeX
@article{Zhang2025,
  author = {Zhang, Shaobo and Zhu, Zebin and Liu, Lianxin and Nashan, Björn and Zhang, Shugeng},
  title = {Biomarker, efficacy and safety analysis of transcatheter arterial chemoembolization combined with atezolizumab and bevacizumab for unresectable hepatocellular carcinoma},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-04058-4}
}
Kostenlos starten →